Shelf Registration Statement Filed with SEC Valencia, Calif, USA, and Melbourne, Australia

Shelf Registration Statement Filed with SEC

Valencia, Calif, USA, and Melbourne, Australia, October 12, 2020 AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH) (the

Company ) advises that it has filed a shelf registration statement on Form S-3 with the United States Securities and Exchange Commission (the SEC ) (a copy of which is attached to this

On the recent one-year anniversary of AVITA s listing on NASDAQ, the Company has for the

first-time become eligible to file the attached S-3 registration statement with the SEC. Under the S-3 registration statement (once it is declared effective by the SEC),

the Company may, in one or more offerings, issue various types of securities, including its common stock, newly designated preferred stock, warrants or units, from time to time over a maximum period of three years.

Filing a S-3 registration statement is common practice for public companies in the United States and it should be noted

Authorized for release by the Chief Financial Officer of AVITA Therapeutics, Inc.

ABOUT AVITA THERAPEUTICS, INC.

AVITA Therapeutics is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds,

and aesthetics indications. AVITA Therapeutics patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient s own skin. The medical devices

work by preparing a RES REGENERATIVE EPIDERMAL SUSPENSION, an autologous suspension comprised of the patient s skin cells necessary to regenerate natural healthy epidermis. This

autologous suspension is then sprayed onto the areas of the patient requiring treatment.

AVITA Therapeutics, Inc. (ARBN 641 28 155) c/o Mertons Corporate Services Pty Ltd Level 7, 330 Collins Street, Melbourne Victoria 3000

AVITA Therapeutics first U.S. product, the

RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns in patients 18

years and older. The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patient s own skin, providing a new way to

treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from

randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 8,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients

and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL Autologous Cell Harvesting Device (https://recellsystem.com/)

for a full description of indications for use and important safety information including contraindications, warnings and precautions.

markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics. The RECELL System is TGA-registered in

Australia and received CE-mark approval in Europe.

To learn more, visit www.avitamedical.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This letter includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as

anticipate, expect, intend, could, may, will, believe, estimate, look forward, forecast, goal, target,

project, continue, outlook, guidance, future, other words of similar meaning and the use of future dates. Forward-looking statements in this letter include, but are not limited to,

statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic,

operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward- looking statement contained in this letter is subject to risks and uncertainties that could cause

actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our

products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the

effects of industry, economic or political conditions outside of the company s control. Investors should not place considerable reliance on the forward-looking statements contained in this letter. Investors are encouraged to read our publicly

available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this letter speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

AVITA Therapeutics, Inc. (ARBN 641 28 155) c/o Mertons Corporate Services Pty Ltd Level 7, 330 Collins Street, Melbourne Victoria 3000

FOR FURTHER INFORMATION:

AVITA Therapeutics, Inc. (ARBN 641 28 155) c/o Mertons Corporate Services Pty Ltd Level 7, 330 Collins Street, Melbourne Victoria 3000